Literature DB >> 18266814

Transgenic Leishmania and the immune response to infection.

L Beattie1, K J Evans1, P M Kaye1, D F Smith1.   

Abstract

Genetic manipulation of single-celled organisms such as the Leishmania parasite enables in depth analysis of the consequences of genotypic change on biological function. In probing the immune responses to infection, use of transgenic Leishmania has the potential to unravel both the contribution of the parasite to the infection process and the cellular interactions and mechanisms that characterize the innate and adaptive immune responses of the host. Here, we briefly review recent technical advances in parasite genetics and explore how these methods are being used to investigate parasite virulence factors, elucidate immune regulatory mechanisms and contribute to the development of novel therapeutics for the leishmaniases. Recent developments in imaging technology, such as bioluminescence and intravital imaging, combined with parasite transfection with fluorescent or enzyme-encoding marker genes, provides a rich opportunity for novel assessment of intimate, real-time host-parasite interactions at a previously unexplored level. Further advances in transgenic technology, such as the introduction of robust inducible gene cassettes for expression in intracellular parasite stages or the development of RNA interference methods for down-regulation of parasite gene expression in the host, will further advance our ability to probe host-parasite interactions and unravel disease-promoting mechanisms in the leishmaniases.

Entities:  

Mesh:

Year:  2008        PMID: 18266814      PMCID: PMC3876712          DOI: 10.1111/j.1365-3024.2008.01020.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  102 in total

1.  Leishmaniasis.

Authors:  Philippe Desjeux
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

Review 2.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  Cathepsin B-like cysteine proteinase-deficient mutants of Leishmania mexicana.

Authors:  G Bart; M J Frame; R Carter; G H Coombs; J C Mottram
Journal:  Mol Biochem Parasitol       Date:  1997-09       Impact factor: 1.759

Review 4.  The immunology of susceptibility and resistance to Leishmania major in mice.

Authors:  David Sacks; Nancy Noben-Trauth
Journal:  Nat Rev Immunol       Date:  2002-11       Impact factor: 53.106

5.  Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor.

Authors:  Phalgun B Joshi; Ben L Kelly; Shaden Kamhawi; David L Sacks; W Robert McMaster
Journal:  Mol Biochem Parasitol       Date:  2002-03       Impact factor: 1.759

6.  The Leishmania major LACK antigen with an immunodominant epitope at amino acids 156 to 173 is not required for early Th2 development in BALB/c mice.

Authors:  Ben L Kelly; Richard M Locksley
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

7.  Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages.

Authors:  Sean M Conrad; Dalit Strauss-Ayali; Ann E Field; Matthias Mack; David M Mosser
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

8.  Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major.

Authors:  Rachel Zufferey; Simon Allen; Tamara Barron; Deborah R Sullivan; Paul W Denny; Igor C Almeida; Deborah F Smith; Salvatore J Turco; Michael A J Ferguson; Stephen M Beverley
Journal:  J Biol Chem       Date:  2003-08-27       Impact factor: 5.157

9.  Comparisons of mutants lacking the Golgi UDP-galactose or GDP-mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in Leishmania major.

Authors:  Althea A Capul; Suzanne Hickerson; Tamara Barron; Salvatore J Turco; Stephen M Beverley
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

10.  Leishmania amastigotes as targets for drug screening.

Authors:  Adriano Monte-Alegre; Ali Ouaissi; Denis Sereno
Journal:  Kinetoplastid Biol Dis       Date:  2006-10-23
View more
  15 in total

Review 1.  Transgenesis and neuronal ablation in parasitic nematodes: revolutionary new tools to dissect host-parasite interactions.

Authors:  J B Lok; D Artis
Journal:  Parasite Immunol       Date:  2008-04       Impact factor: 2.280

2.  Regulated expression of the Leishmania major surface virulence factor lipophosphoglycan using conditionally destabilized fusion proteins.

Authors:  Luciana Madeira da Silva; Katherine L Owens; Silvane M F Murta; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-21       Impact factor: 11.205

3.  Postgenomic research on leishmaniasis: a critical self-appraisal.

Authors:  Paul M Kaye; Jenefer M Blackwell
Journal:  Trends Parasitol       Date:  2008-08-04

4.  B cell: T cell interactions occur within hepatic granulomas during experimental visceral leishmaniasis.

Authors:  John W J Moore; Lynette Beattie; Jane E Dalton; Benjamin M J Owens; Asher Maroof; Mark C Coles; Paul M Kaye
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

5.  Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine.

Authors:  Gustavo Domínguez-Bernal; Pilar Horcajo; José A Orden; Ricardo De La Fuente; Aldara Herrero-Gil; Lara Ordóñez-Gutiérrez; Javier Carrión
Journal:  Vet Res       Date:  2012-08-09       Impact factor: 3.683

6.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

7.  Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.

Authors:  Laura Ramirez; Laura Corvo; Mariana C Duarte; Miguel A Chávez-Fumagalli; Diogo G Valadares; Diego M Santos; Camila I de Oliveira; Marta R Escutia; Carlos Alonso; Pedro Bonay; Carlos A P Tavares; Eduardo A F Coelho; Manuel Soto
Journal:  Parasit Vectors       Date:  2014-01-02       Impact factor: 3.876

Review 8.  Genetically modified organisms and visceral leishmaniasis.

Authors:  Rudra Chhajer; Nahid Ali
Journal:  Front Immunol       Date:  2014-05-14       Impact factor: 7.561

Review 9.  Vaccines for canine leishmaniasis.

Authors:  Faeze Foroughi-Parvar; Gholamreza Hatam
Journal:  Adv Prev Med       Date:  2014-12-31

10.  New insights into experimental visceral leishmaniasis: Real-time in vivo imaging of Leishmania donovani virulence.

Authors:  Guilherme D Melo; Sophie Goyard; Hervé Lecoeur; Eline Rouault; Pascale Pescher; Laurence Fiette; Alexandre Boissonnas; Paola Minoprio; Thierry Lang
Journal:  PLoS Negl Trop Dis       Date:  2017-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.